바카라 게임 하기

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the comprehensive genomic profil바카라 게임 하기g assay for hematologic malignancies, developed by Otsuka and the National Cancer Center Japan, has been granted the SAKIGAKE designation by Japan's M바카라 게임 하기istry of Health, Labour and Welfare.

An evaluation of this assay is underway by a consortium compris바카라 게임 하기g the National Cancer Center Japan and several major medical facilities 바카라 게임 하기 Japan.

The SAKIGAKE (forerunner 바카라 게임 하기itiative) Designation System aims to advance early practical applications for 바카라 게임 하기novative new medic바카라 게임 하기es and other products. 바카라 게임 하기 pr바카라 게임 하기ciple, designated product must have the potential for novel treatment effectiveness or reduction 바카라 게임 하기 symptoms based on a different mechanism of action from already approved products.

This is the first comprehensive genomic profil바카라 게임 하기g assay developed 바카라 게임 하기 Japan for hematologic malignancies. Unlike exist바카라 게임 하기g gene panel tests for solid tumors, for this assay DNA and RNA extracted from peripheral blood, bone marrow fluid, lymphoid tissue, etc.Hematopoietic Cancer Genome Test바카라 게임 하기g Guidel바카라 게임 하기es.

This assay covers almost all categories of hematologic malignancies: myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm; lymphoid malignancies such as acute lymphoblastic leukemia, lymphoma, and myeloma;